MX2017012470A - Metodos para estratificacion de pacientes para tratamiento con agonistas del receptor alfa de acido retinoico. - Google Patents

Metodos para estratificacion de pacientes para tratamiento con agonistas del receptor alfa de acido retinoico.

Info

Publication number
MX2017012470A
MX2017012470A MX2017012470A MX2017012470A MX2017012470A MX 2017012470 A MX2017012470 A MX 2017012470A MX 2017012470 A MX2017012470 A MX 2017012470A MX 2017012470 A MX2017012470 A MX 2017012470A MX 2017012470 A MX2017012470 A MX 2017012470A
Authority
MX
Mexico
Prior art keywords
treatment
agonists
patients
methods
alfa
Prior art date
Application number
MX2017012470A
Other languages
English (en)
Other versions
MX391949B (es
Inventor
Wei Chen Mei
Collins Cindy
Lucas EATON Matthew
G Guenther Matthew
KE Nan
LOPEZ Jeremy
R Mckeown Michael
A Orlando David
Original Assignee
Syros Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syros Pharmaceuticals Inc filed Critical Syros Pharmaceuticals Inc
Publication of MX2017012470A publication Critical patent/MX2017012470A/es
Publication of MX391949B publication Critical patent/MX391949B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención proporciona métodos que definen poblaciones celulares que son sensibles a agonistas RARA e identifican subgrupos de pacientes que se beneficiarían del tratamiento con agonistas RARA. La invención también proporciona composiciones farmacéuticas empacadas que comprenden un agonista RARA e instrucciones para determinar si tal agonista es apropiado para uso en el tratamiento.
MX2017012470A 2015-03-31 2016-03-31 Metodos para estratificacion de pacientes para tratamiento con agonistas del receptor alfa de acido retinoico. MX391949B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562140999P 2015-03-31 2015-03-31
US201562268203P 2015-12-16 2015-12-16
PCT/US2016/025256 WO2016161107A1 (en) 2015-03-31 2016-03-31 METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-α AGONISTS

Publications (2)

Publication Number Publication Date
MX2017012470A true MX2017012470A (es) 2018-03-23
MX391949B MX391949B (es) 2025-03-21

Family

ID=57006493

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017012470A MX391949B (es) 2015-03-31 2016-03-31 Metodos para estratificacion de pacientes para tratamiento con agonistas del receptor alfa de acido retinoico.
MX2022005020A MX2022005020A (es) 2015-03-31 2017-09-28 Metodos para estratificacion de pacientes para tratamiento con agonistas del receptor alfa de acido retinoico.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022005020A MX2022005020A (es) 2015-03-31 2017-09-28 Metodos para estratificacion de pacientes para tratamiento con agonistas del receptor alfa de acido retinoico.

Country Status (14)

Country Link
US (5) US9845508B2 (es)
EP (2) EP3967305A1 (es)
JP (4) JP6952604B2 (es)
KR (1) KR20170132248A (es)
CN (2) CN107613969B (es)
AU (3) AU2016243702B2 (es)
BR (3) BR112017020745A2 (es)
CA (1) CA2981518C (es)
ES (1) ES2901792T3 (es)
HU (1) HUE057325T2 (es)
IL (3) IL254697B (es)
MX (2) MX391949B (es)
PL (1) PL3277272T3 (es)
WO (1) WO2016161107A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014145295A1 (en) 2013-03-15 2014-09-18 Avisenna Cosmetics, Llc Topical compositions for reducing aging effects
MX391949B (es) 2015-03-31 2025-03-21 Syros Pharmaceuticals Inc Metodos para estratificacion de pacientes para tratamiento con agonistas del receptor alfa de acido retinoico.
JP7034085B2 (ja) * 2016-04-08 2022-03-11 サイロス ファーマシューティカルズ， インコーポレイテッド Ａｍｌ及びｍｄｓの治療のためのｒａｒａアゴニスト
US9868994B2 (en) 2016-04-08 2018-01-16 Syros Pharmaceuticals, Inc. Methods of stratifying patients for treatment with retinoic acid receptor-α agonists
TW201823471A (zh) * 2016-10-06 2018-07-01 美商錫羅斯製藥公司 以視黃酸受體-α促效劑及抗CD38抗體治療病患之方法
WO2018136961A1 (en) * 2017-01-23 2018-07-26 Syros Pharmaceuticals Inc. METHODS OF TREATING PATIENTS WITH A RETINOIC ACID RECEPTOR-α AGONIST AND AN ANTI-CD38 ANTIBODY
JP2019043865A (ja) * 2017-08-31 2019-03-22 ひまわり製薬株式会社 ざ瘡様疾患を治療又は予防するための皮膚外用組成物
WO2020069187A1 (en) * 2018-09-28 2020-04-02 The Children's Medical Center Corporation Combination therapy for acute myeloid leukemia
CA3188102A1 (en) * 2020-08-06 2022-02-10 Qing KANG-FORTNER Therapies for treating aml and uses of rara agonists, hypomethylating agents, and bcl-2 inhibitors
CN112390731B (zh) * 2020-11-16 2022-11-25 成都大学 一种具有多靶点的维甲酸类衍生物及其制备方法与应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0170105B1 (en) 1984-07-07 1990-10-17 Koichi Prof. Dr. Shudo Benzoic acid derivatives
US5089509A (en) 1988-09-15 1992-02-18 Allergan, Inc. Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
JP2752630B2 (ja) 1988-03-29 1998-05-18 大鵬薬品工業株式会社 新規安息香酸誘導体及びその製造方法
AU1666192A (en) 1991-03-22 1992-10-21 Sloan-Kettering Institute For Cancer Research Methods for detection and treatment of cancer
US5759785A (en) 1992-05-14 1998-06-02 Baylor College Of Medicine Method of identifying hormone antagonists and agonists
US5455265A (en) 1993-02-11 1995-10-03 Allergan, Inc. Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
US5824685A (en) 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
FR2739777B1 (fr) 1995-10-11 1997-11-14 Cird Galderma Ligand antagoniste rar-gamma ou agoniste rar-alpha en tant qu'inhibiteur d'apoptose
US5675024A (en) 1995-11-22 1997-10-07 Allergan Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4,-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity
US5965606A (en) 1995-12-29 1999-10-12 Allergan Sales, Inc. Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
KR100485642B1 (ko) 1996-03-18 2005-09-30 에자이 가부시키가이샤 축합고리함유카르복실산유도체
ATE471150T1 (de) 1996-03-26 2010-07-15 Kopreski Michael S Methoden aus plasma oder serum extrahierte extrazelluraere rna zur diagnoseüberwachung oder evaluation von krebs verwenden
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
CA2307613A1 (en) 1997-10-22 1999-04-29 Eisai Co., Ltd. Retinoic acid agonist as a prophylactic and therapeutic agent for nephritis
AU1853600A (en) 1999-01-06 2000-07-24 Choong-Chin Liew Method for the detection of gene transcripts in blood and uses thereof
TWI281911B (en) 2000-04-04 2007-06-01 Allergan Inc Treatment of tumors with RARalpha selective retinoid compounds in combination with other anti-tumor agents
AU2002328226A1 (en) * 2001-09-17 2003-04-01 Angiogene Inc. Modulation of retinoic acid receptor gene expression and therapeutic uses thereof
JP5113038B2 (ja) 2006-03-23 2013-01-09 テムリック株式会社 癌治療用キットおよび癌治療用医薬組成物
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
WO2008120711A1 (ja) * 2007-03-30 2008-10-09 Tmrc Co., Ltd. タミバロテンカプセル剤
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
US20100099084A1 (en) 2008-10-17 2010-04-22 Maher Albitar Detection of npm1 nucleic acid in acellular body fluids
US20130165520A1 (en) * 2010-02-11 2013-06-27 University De Montreal Hybrid Molecule Having Mixed Retinoic Acid Receptor Agonism and Histone Deacetylase Inhibitory Properties
NZ702415A (en) * 2012-06-07 2016-04-29 Children’S Hospital Los Angeles Methods for treating neutropenia using retinoid agonists
US20140296218A1 (en) 2012-10-25 2014-10-02 Whitehead Institute For Biomedical Research Super-enhancers and methods of use thereof
US20140287932A1 (en) 2012-10-25 2014-09-25 Whitehead Institute For Biomedical Research Super-enhancers and methods of use thereof
US20140272956A1 (en) 2013-03-15 2014-09-18 Abbott Molecular Inc. Method for amplification and assay of rna fusion gene variants, method of distinguishing same and related primers, probes, and kits
CA2919513A1 (en) 2013-07-15 2015-01-22 Matthew J. Goldstein Medical uses of cd38 agonists
IL278381B2 (en) 2013-12-06 2024-08-01 Celgene Corp Methods for determining the effectiveness of a drug for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancer
EP3089743B1 (en) 2013-12-30 2018-07-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of an arsenic compound and at least one retinoid for treating acute myeloid leukemia
EP3267969A1 (en) 2015-03-09 2018-01-17 King's College London Combination therapy with rar alpha agonists for enhancing th1 response
MX391949B (es) 2015-03-31 2025-03-21 Syros Pharmaceuticals Inc Metodos para estratificacion de pacientes para tratamiento con agonistas del receptor alfa de acido retinoico.
DK3380086T3 (da) 2015-11-25 2021-11-22 Io Therapeutics Inc Cyp26-resistente rar-alpha-selektive agonister i behandling af cancer
US9868994B2 (en) 2016-04-08 2018-01-16 Syros Pharmaceuticals, Inc. Methods of stratifying patients for treatment with retinoic acid receptor-α agonists
JP7034085B2 (ja) 2016-04-08 2022-03-11 サイロス ファーマシューティカルズ， インコーポレイテッド Ａｍｌ及びｍｄｓの治療のためのｒａｒａアゴニスト
TW201823471A (zh) 2016-10-06 2018-07-01 美商錫羅斯製藥公司 以視黃酸受體-α促效劑及抗CD38抗體治療病患之方法
WO2018136961A1 (en) 2017-01-23 2018-07-26 Syros Pharmaceuticals Inc. METHODS OF TREATING PATIENTS WITH A RETINOIC ACID RECEPTOR-α AGONIST AND AN ANTI-CD38 ANTIBODY

Also Published As

Publication number Publication date
CN116059365A (zh) 2023-05-05
RU2017134582A (ru) 2019-04-04
KR20170132248A (ko) 2017-12-01
US20180087115A1 (en) 2018-03-29
ES2901792T3 (es) 2022-03-23
RU2017134582A3 (es) 2019-12-13
PL3277272T3 (pl) 2022-01-24
IL294449A (en) 2022-09-01
IL294449B1 (en) 2024-01-01
US11447831B2 (en) 2022-09-20
US20200392583A1 (en) 2020-12-17
AU2024216311A1 (en) 2024-09-12
MX2022005020A (es) 2022-05-16
AU2022200059A1 (en) 2022-02-03
CN107613969A (zh) 2018-01-19
US20160355888A1 (en) 2016-12-08
EP3967305A1 (en) 2022-03-16
CA2981518A1 (en) 2016-10-06
CA2981518C (en) 2024-06-25
IL254697A0 (en) 2017-11-30
BR122023024814A2 (pt) 2024-02-20
JP2024081713A (ja) 2024-06-18
WO2016161107A1 (en) 2016-10-06
EP3277272A4 (en) 2018-09-26
EP3277272A1 (en) 2018-02-07
JP6952604B2 (ja) 2021-10-20
AU2016243702B2 (en) 2021-10-07
AU2016243702A1 (en) 2017-10-26
CN107613969B (zh) 2022-07-22
JP2020203911A (ja) 2020-12-24
BR122023024813A2 (pt) 2024-02-20
BR112017020745A2 (en) 2018-07-17
US20230042181A1 (en) 2023-02-09
IL309066A (en) 2024-02-01
IL254697B (en) 2022-08-01
JP2018514517A (ja) 2018-06-07
IL294449B2 (en) 2024-05-01
AU2022200059B2 (en) 2024-05-23
EP3277272B1 (en) 2021-08-04
JP2022185101A (ja) 2022-12-13
HUE057325T2 (hu) 2022-04-28
MX391949B (es) 2025-03-21
US20180187271A1 (en) 2018-07-05
US10167518B2 (en) 2019-01-01
US9845508B2 (en) 2017-12-19
US10697025B2 (en) 2020-06-30

Similar Documents

Publication Publication Date Title
MX2017012470A (es) Metodos para estratificacion de pacientes para tratamiento con agonistas del receptor alfa de acido retinoico.
MX2015000990A (es) Analogos del glucagon.
CL2015003290A1 (es) Nuevos agonistas del receptor de somatostatina subtipo 4 (sstr4).
NI201700034A (es) Indazoles sustituidos con benzilo como inhibidores de bub1.
UY35500A (es) Indazoles sustituidos con heteroarilo
EA201691259A1 (ru) РЕГУЛЯТОРЫ Nrf2
BR112017003419A2 (pt) formulação de anticorpo anti-il-4r-alfa estável
MX2016010998A (es) Terapia celular adoptiva que usa un agonista de receptor huérfano gamma relacionado con receptor de ácido retinoico y métodos terapéuticos relacionados.
CL2016002375A1 (es) Anticuerpos antagonistas dirigidos contra el péptido relacionado con el gen de calcitonina y métodos que usan los mismos
CO2017002160A2 (es) Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
CL2015002724A1 (es) Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23
BR112016024494A2 (pt) análogos de peptídeo com sonda(s) de aminoácidos ramificados
UY35499A (es) Indazoles sustituidos con diaminoheteroarilo
MX2021000773A (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos de uso del mismo.
ECSP16012582A (es) Compuestos heterocíclicos y métodos de uso
PE20160549A1 (es) Formulacion liquida estable de etelcalcetida (amg 416)
BR112014020113A8 (pt) Composições farmacêuticas e método para diminuir a frequência de micção
BR112013003590A2 (pt) método de ativar células t regulatórias com agonistas de receptoe adrenérgico alfa-2b
CL2016001570A1 (es) Uso de un antagonista de receptores de opioides con actividad %u039a y vortioxetina para el tratamiento de trastorno depresivo con características melancólicas
MX386107B (es) Composiciones para el cuidado bucal.
BR112018070547A2 (pt) agonistas de rara para o tratamento de aml e mds
CL2016001965A1 (es) Composición coadyuvante anticancerígena que contiene rip3 expresión del promotor como ingrediente activo, método para seleccionar composición coadyuvante anticancerígena para mejorar la sensibilidad de droga anticancerigena, promoviendo la expresión rip3, y metodo para seguimiento de sensibilidad; medicamento contra el cáncer
AR089114A1 (es) PREVENCION DE LOS EFECTOS ADVERSOS CAUSADOS POR LOS ANTICUERPOS BIESPECIFICOS EpCAMxCD3
TWD177942S (zh) 長度測量裝置
UY35823A (es) Profármacos de antagonista de nmda